BYOOVIZ was evaluated for biosimilarity in an nAMD clinical study and was granted approval for macular edema following RVO and mCNV through a process called "extrapolation." Extrapolation of clinical data to other indications of the reference product is considered in light of the totality of evidence and must be scientifically justified.7
Indications and Important
Safety Information
BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Please see full Prescribing Information.
BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Please see full Prescribing Information.